ResApp Health (ASX:RAP) - Managing Director & CEO, Tony Keating
Managing Director & CEO, Tony Keating
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) completes recruitment for its US-based SARS-CoV2 clinical study, COVID-Cough
  • The trial collects audio cough recordings and symptoms for 122 PCR-confirmed COVID-19 positive cases and 139 negative cases
  • The clinical study is gathering data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone
  • ResApp last traded at 6.2 cents on January 10

ResApp Health (RAP) has completed recruitment for its US-based SARS-CoV2 clinical study, COVID-Cough.

The US-based COVID-Cough Pilot clinical study aims to collect data to train an algorithm to identify COVID-19 through cough sounds recorded on a smartphone using a gold-standard PCR pathology test.

It was successful in collecting audio cough recordings and self-reported symptoms for 122 polymerase chain reaction (PCR) confirmed COVID-19 positive cases and 139 negative cases.    

CEO and Managing Director Dr Tony Keating said the company appreciates the support of participants who enrolled in the study and the work of its partners, Phosphorus and Covid Clinic, for assisting with recruitment.

“This US data, as well as data from our recently completed Indian clinical study and our datasets collected pre-COVID-19, provides us with a high-quality clinical dataset to build, train and validate algorithms for detection and monitoring of COVID-19,” said Dr Keating.

“As the fourth wave of COVID-19 spreads worldwide, our team is working hard to deliver algorithms for a much-needed, instant smartphone-based screening test and patient monitoring tools that could change the way the world lives with this virus.”

Shares in ResApp Health remain steady today at 6.2 cents each as of 12:04 pm AEDT.

RAP by the numbers
More From The Market Herald
Limeade (ASX:LME) - CEO, Henry Albrecht

" Limeade (ASX:LME) maintains FY21 financial guidance in quarterly report

Limeade (ASX:LME) has maintained its FY21 revenue guidance of $50 million to $53 million, but posted…
Sihayo Gold (ASX:SIH) - Executive Chairman, Colin Moorhead

" Sihayo Gold (ASX:SIH) secures further interim funding

Sihayo Gold (ASX:SIH) has secured interim funding from its shareholder, PT Saratoga Investama Sedaya Tbk.

" Alchemy Resources (ASX:ALY) commences aircore drilling at Karonie

Aircore drilling is underway at Alchemy Resources' (ASX:ALY) Karonie gold project 110 kilometres east of Kalgoorlie,…
Little Green Pharma (ASX:LGP) - Managing Director, Fleta Solomon

" Little Green Pharma (ASX:LGP) seeks to expand to Greece

Little Green Pharma (ASX:LGP) seeks to expand to Greece